Billionaire Ken Griffin calls tariffs a ‘painfully regressive tax,’ hitting working class Americans the hardest

Billionaire Ken Griffin calls tariffs a ‘painfully regressive tax,’ hitting working class Americans the hardest


Citadel CEO Ken Griffin speaks during the Semafor World Economy Summit 2025 at Conrad Washington on April 23, 2025 in Washington, DC.
Kayla Bartkowski | Getty Images

Billionaire Ken Griffin, founder and CEO of the Citadel hedge fund, said working class Americans will bear the brunt of President Donald Trump’s punitive tariffs on U.S. trading partners.

“Tariffs hit the pocketbook of hardworking Americans the hardest,” Griffin said on CNBC’s “Closing Bell” Wednesday. “It’s like a sales tax for the American people. It’s going to hit those who are working the hardest to make ends meet. That’s my big issue with tariffs. It’s such a painfully regressive tax.”

Trump rolled out shockingly high levies on imports last month, triggering extreme swings on Wall Street. The president later went on to announce a 90-day pause on much of the increase, except for China, as the White House sought to strike deals with major trading partners. Trump has slapped tariffs of 145% on imported Chinese goods this year, prompting China to impose retaliatory levies of 125%.

Griffin, whose hedge fund managed more than $65 billion at the start of 2025, voted for Trump and was a megadonor to Republican politicians. But he has also criticized Trump’s trade policy, saying it risks spoiling the “brand” of the United States and its government bond market.

“The reason the American voters elected President Trump was because of the failed economic policies of Joe Biden and the inflationary shock that reduced the real incomes of every American household,” Griffin said. “The president really does have to focus on managing inflation, because I think it’s front and center, the primary score card that American voters are going to think about when it comes to this midterm election.”

The Wall Street titan said there is a “modest” risk of stagflation as higher tariffs create both inflationary pressures and slow down the economy. He said the trajectory of the economy largely depends on how Trump’s economic policy develops.

As laid out by Treasury Secretary Scott Bessent, Trump’s economic program takes a three-pronged approach: trade, tax cuts and deregulation.

“The question is, will all three of those come together to give us the growth that we need in our economy?,” Griffin asked. “That’s the real question we’re going to face over the next two years.”



Source

Stocks making the biggest moves midday: Target, Intel, Medtronic, Palantir, La-Z-Boy and more
Finance

Stocks making the biggest moves midday: Target, Intel, Medtronic, Palantir, La-Z-Boy and more

Here are some of the stocks posting the biggest moves in midday trading Wednesday. Palantir Technologies — The defense technology company headed for a sixth consecutive losing day, dropping more than 2% on Wednesday. If Palantir closes in negative territory, that will mark its first six-day losing run since April 2024. Shares have more than […]

Read More
Stocks making the biggest premarket moves: Target, Lowe’s, Snowflake and more
Finance

Stocks making the biggest premarket moves: Target, Lowe’s, Snowflake and more

Check out the companies making the biggest moves in premarket trading: Target — The big box retailer sank 10.5% after announcing CEO Brian Cornell will be replaced by Chief Operating Officer Michael Fiddelke on Feb.1. Target also posted a second-quarter earnings and revenue beat, although its sales and traffic declined, and reiterated its full-year outlook. […]

Read More
Stocks making the biggest moves midday: Home Depot, Intel, Viking Therapeutics, Nvidia and more
Finance

Stocks making the biggest moves midday: Home Depot, Intel, Viking Therapeutics, Nvidia and more

These are some of the stocks making the biggest moves during midday trading: Viking Therapeutics — Shares tumbled 42% after phase 2 trial results showed Viking’s experimental oral obesity drug had more side effects than expected. About 20% of the patients in the trial quit using the drug due to symptoms such as nausea and […]

Read More